Incorrect dosing reported 5-12% of the time.
Higher mortality, stroke and major hemorrhage events in patients that have received incorrect doses of fibrinolytic therapy.
All fibrinolytic agents function by generating plasmin, which breaks down fibrin cross-links and yields fibrin degradation products.
Degradation products can themselves be thrombogenic so patients given fibrinolytic so should also be given anti-thrombotic therapy with unfractionated heparin or low molecular weight heparin.